Out of the survey’s 200 physician respondents, 61 percent agreed or strongly agreed that branded drug therapies have a role in reducing the cost of patient care when used appropriately.
“Drug spend is not considered today in most contracts between ACOs and payors,” Mark Mozeson, a partner at Oliver Wyman and survey co-director, said in a news release. “Many in the industry expect that to change in the near future. And as it does, drug makers will have the opportunity in many cases to move away from negotiating unit price with commercial health plans and instead contract directly with providers based on outcomes and ability to manage total disease costs. Their ability to demonstrate value will determine whether they have a seat at the table.”
More Articles on ACOs:
5 Challenges to the Spread of ACOs
Methodist Health System’s Approach to PCMHs and ACOs: Q&A With Dr. Melissa Gerdes
12 ACOs Form Statewide Association in Florida
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
